Highly active antiretroviral therapy (HAART) has led to profound decreases
in morbidity and mortality rates in human immunodeficiency virus type 1 (HI
V-1)-infected persons, at least in the developed world. Many infected perso
ns have plasma levels of HIV-1 RNA that are less than the limits of detecti
on of most clinical assays as a result of combination antiretroviral therap
y. Nonetheless, HIV-1 has not been eradicated by HAART. This has been shown
to be because of latent HIV-1 replication-competent provirus in resting CD
4(+) T lymphocytes, cryptic viral replication below the limits of detection
of most clinical assays, and, possibly, the presence of viral sanctuary si
tes. An understanding of these reservoirs for HIV-1 in the setting of viral
ly suppressive HAART will be critical for the development of new approaches
to induce HIV-1 remissions and for the exploration of the possibility of v
iral eradication in the future.